Sacubitril / Valsartan clinical trials
Sacubitril / Valsartan is named as an intervention in 9 current clinical trials in our China, Poland, South Korea, Spain and Egypt registers. 7 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Beijing Friendship Hospital (1). The most-studied condition is Sacubitril/Valsartan.
NICE appraisals of Sacubitril / Valsartan
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Sacubitril / Valsartan. 1 is current, and 1 of it recommends it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction NICE TA388 | Optimised | 27 Apr 2016 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Sacubitril / Valsartan
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 6 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Sacubitril / Valsartan
9 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Sacubitril / Valsartan across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
6 single-substance products containing Sacubitril / Valsartan on the HPRA medicines list.
- Entresto 24 mg/26 mg film-coated tabletsNovartis Europharm Limited · EU/1/15/1058/001
- Entresto 49 mg/51 mg film-coated tabletsNovartis Europharm Limited · EU/1/15/1058/002-004
- Entresto 97 mg/103 mg film-coated tabletsNovartis Europharm Limited · EU/1/15/1058/005-007
- Neparvis 24 mg/26 mg film-coated tabletsNovartis Europharm Limited · EU/1/16/1103/001
- Neparvis 49 mg/51 mg film-coated tabletsNovartis Europharm Limited · EU/1/16/1103/002-004
Supply shortages
No entry for Sacubitril / Valsartan in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Sacubitril / Valsartan
18 conditionsAll 18 conditions
| Condition (as registered) | Trials |
|---|---|
| Sacubitril/Valsartan | 2 |
| Essential Hypertension | 2 |
| Heart Failure | 2 |
| Hypertension | 1 |
| Obesity | 1 |
| Coronary Artery Disease | 1 |
| Ischemic Mitral Regurgitation | 1 |
| Angiotensin Receptor/Neprilysin Inhibitor | 1 |
| Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) | 1 |
| Heart Failure With Moderately Reduced Ejection Fraction | 1 |
| Breast Cancer | 1 |
| Neoplasm, Breast | 1 |
| Breast Diseases | 1 |
| Antihypertensive Agents | 1 |
| Heart Failure Due to Coronary Artery Disease | 1 |
| Valvular Cardiomyopathy | 1 |
| Prosthetic Heart Valve | 1 |
| Reduced Ejection Fraction | 1 |
Sponsors
lead sponsor per trialBy country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 2 |
| Clinical trials in Poland | 2 | 2 |
| Clinical trials in South Korea | 2 | 2 |
| Clinical trials in Spain | 1 | 0 |
| Clinical trials in Egypt | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Sacubitril / Valsartan trials
How many clinical trials are testing Sacubitril / Valsartan?
9 current trials in our China, Poland, South Korea, Spain and Egypt registers name Sacubitril / Valsartan as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Sacubitril / Valsartan trials recruiting patients?
Yes. 7 of the 9 trials are recruiting: 2 with sites in China, 2 with sites in Poland, 2 with sites in South Korea and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Sacubitril / Valsartan clinical trials?
Beijing Friendship Hospital (1), China National Center for Cardiovascular Diseases (1), Wuhan Createrna Science and Technology Co., Ltd (1) and Puerta de Hierro University Hospital (1), among 9 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is Sacubitril / Valsartan licensed in Ireland?
Yes. The HPRA medicines list includes 6 single-substance products containing Sacubitril / Valsartan, for example Entresto 24 mg/26 mg film-coated tablets (Novartis Europharm Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Sacubitril / Valsartan shortage?
Not in the lists we track: Sacubitril / Valsartan has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Sacubitril / Valsartan works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Sacubitril / Valsartan works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Sacubitril / Valsartan (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.